Roy Buchanan
Stock Analyst at Citizens Capital Markets
(0.70)
# 3,678
Out of 4,814 analysts
56
Total ratings
23.08%
Success rate
-26.42%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANTX AN2 Therapeutics | Reiterates: Market Outperform | $5 | $1.25 | +300.00% | 8 | Mar 26, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $1.74 | +934.48% | 3 | Mar 14, 2025 | |
| CDTX Cidara Therapeutics | Initiates: Market Outperform | $46 | $19.44 | +136.63% | 1 | Mar 12, 2025 | |
| CVAC CureVac | Reiterates: Market Outperform | $16 | $3.14 | +410.37% | 8 | Feb 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $43.46 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $0.96 | +314.98% | 3 | Feb 11, 2025 | |
| ENTA Enanta Pharmaceuticals | Reiterates: Market Outperform | $21 | $5.13 | +309.36% | 12 | Feb 11, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Outperform | $23 → $14 | $0.73 | +1,825.72% | 1 | Jan 30, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Market Outperform | $33 | $6.38 | +417.24% | 1 | Jan 10, 2025 | |
| HOOK HOOKIPA Pharma | Maintains: Market Outperform | $24 → $7 | $0.77 | +805.21% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $5 | $3.15 | +58.98% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $25 → $27 | $10.30 | +162.14% | 5 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $593.60 | -24.53% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $7.68 | +108.33% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.89 | - | 2 | Feb 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $420 | $2.75 | +15,172.73% | 1 | Sep 14, 2021 |
AN2 Therapeutics
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $1.25
Upside: +300.00%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $1.74
Upside: +934.48%
Cidara Therapeutics
Mar 12, 2025
Initiates: Market Outperform
Price Target: $46
Current: $19.44
Upside: +136.63%
CureVac
Feb 14, 2025
Reiterates: Market Outperform
Price Target: $16
Current: $3.14
Upside: +410.37%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $43.46
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $0.96
Upside: +314.98%
Enanta Pharmaceuticals
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $21
Current: $5.13
Upside: +309.36%
Ironwood Pharmaceuticals
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $0.73
Upside: +1,825.72%
ABIVAX Société Anonyme
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $6.38
Upside: +417.24%
HOOKIPA Pharma
Nov 21, 2024
Maintains: Market Outperform
Price Target: $24 → $7
Current: $0.77
Upside: +805.21%
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $3.15
Upside: +58.98%
Nov 3, 2023
Maintains: Market Outperform
Price Target: $25 → $27
Current: $10.30
Upside: +162.14%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $593.60
Upside: -24.53%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $7.68
Upside: +108.33%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.89
Upside: -
Sep 14, 2021
Initiates: Market Outperform
Price Target: $420
Current: $2.75
Upside: +15,172.73%